Vabysmo vs Tepezza
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Tepezza | |
|---|---|---|
| Generic name | faricimab | teprotumumab |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | IGF-1R Inhibitor (Biologic) |
| Treats | Wet macular degeneration, diabetic macular edema | Thyroid eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | Amgen |
| Year approved | 2022 | 2020 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Muscle spasms, Nausea, Hair loss, Hearing problems |
Frequently asked questions
Is Vabysmo or Tepezza better?
Neither is universally "better." Vabysmo (faricimab) and Tepezza (teprotumumab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Tepezza?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.